Investment
Features
FeesSafety
Academy
More
Pluang+

Radiant Logistics to discuss Q4 and full-year 2026 financial results in Sept 14 call

Company Fundamentals
08 Sep 2026
PRNewsWire
View Source
Neutral
Radiant Logistics to discuss Q4 and full-year 2026 financial results in Sept 14 call

Radiant Logistics, a global transportation and logistics services company, will hold a conference call on September 14, 2026, to review its financial results for the quarter and fiscal year ending June 30, 2026. The call, hosted by CEO Bohn Crain, is open to all investors and media, providing insights into the company's performance and future outlook. A replay and webcast will be available for those unable to attend live. This event is important for investors tracking Radiant's growth and market position in North America and beyond.

More News

Chewy expects Q2 2026 EPS of $0.36 and $3.32B revenue amid growth and cost challenges.

Chewy expects Q2 2026 EPS of $0.36 and $3.32B revenue amid growth and cost challenges.

Chewy will report its Q2 2026 earnings on September 9, with analysts expecting earnings per share (EPS) of $0.36, a 9.1% increase year-over-year, and revenue of $3.32 billion, up 6.8%. Growth is driven by its Autoship subscription program and expansi...

Company Fundamentals
Neutral
1 hour ago
Tarsus Pharmaceuticals gains analyst boost after acquiring Alkeus and expanding Stargardt's disease drug pipeline.

Tarsus Pharmaceuticals gains analyst boost after acquiring Alkeus and expanding Stargardt's disease drug pipeline.

Tarsus Pharmaceuticals recently acquired Alkeus Pharmaceuticals, gaining worldwide rights to gildeuretinol, a promising Phase 3 drug for Stargardt's disease, which currently lacks FDA-approved treatments. Analyst Jefferies raised Tarsus' price target...

Analyst Insights
Bullish
1 hour ago
The Trade Desk cuts 15% workforce amid S&P 500 removal but posts strong revenue growth.

The Trade Desk cuts 15% workforce amid S&P 500 removal but posts strong revenue growth.

The Trade Desk is undergoing restructuring with a 15% workforce reduction costing up to $51 million, following its removal from the S&P 500 index which caused a 2% stock drop. Despite these challenges, the company shows strong financial health, repor...

Market News
Neutral
2 hours ago
GameStop beats Q2 revenue estimates with strong collectibles growth despite overall sales decline.

GameStop beats Q2 revenue estimates with strong collectibles growth despite overall sales decline.

GameStop reported Q2 2026 revenue of $790.20 million, beating analyst estimates but showing a 19% year-over-year decline due to a strong prior year and strategic store closures. The company's Collectibles segment grew 57% to $356.30 million, offsetti...

Company Fundamentals
Bullish
3 hours ago
Raymond James sets Dyne Therapeutics price target at $37, signaling 80% upside on clinical progress.

Raymond James sets Dyne Therapeutics price target at $37, signaling 80% upside on clinical progress.

Raymond James analyst Michael Freeman raised Dyne Therapeutics' price target to $37, suggesting an 80.75% upside from its current price around $20.60. The clinical-stage biotech is advancing treatments for muscle diseases like Myotonic Dystrophy Type...

Analyst Insights
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App